Silenus changes hands:
This article was originally published in Clinica
ICI Australia has agreed to sell its diagnostics subsidiary, Silenus Laboratories, to Amrad Operations for an undisclosed sum. ICI said the sale, which should be completed by mid- August, would allow Silenus to prosper as part of a larger Australian biotechnology business.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.